{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-091407","form_type":"8-K","ticker":"ZURA","cik":"0001855644","company_name":"Zura Bio Ltd","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.818494+00:00","generated_at":"2026-06-11T12:45:34.101259+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Zura Bio reports Q2 2023 cash of $112.8M; advancing ZB-106 to Phase 2 in 2H 2024","bullets":["Cash and equivalents $112.8M at June 30, 2023, up from $1.6M at Dec 31, 2022; sufficient to fund operations through 2026.","R&D expenses $28.2M in Q2 2023 vs $0.1M in Q2 2022, driven by ZB-106 license from Eli Lilly.","G&A expenses $5.7M in Q2 2023 vs $0.8M in Q2 2022, due to higher compensation and legal/accounting costs.","Pipeline: ZB-106 Phase 2 trials for systemic sclerosis and hidradenitis suppurativa expected to start in 2H 2024; ZB-168 and ZB-880 Phase 2 trials in 2024.","Completed ~$80M private placement in June 2023; joined Russell 2000/3000 indexes."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-091407","json":"https://secwatch.observer/filing/0001104659-23-091407.json","markdown":"https://secwatch.observer/filing/0001104659-23-091407.md","text":"https://secwatch.observer/filing/0001104659-23-091407.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855644/000110465923091407/0001104659-23-091407-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855644/000110465923091407/tm2323743d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T12:45:34.101259+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"226ac46fe9904818d12319da414947d31eb6f81e","claim":"Zura Bio Ltd reported financial results for second quarter ended June 30, 2023.","evidence_excerpt":"Zura Bio Limited (the “Company”) issued a press release announcing its second quarter 2023 results. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated herein by reference.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1855644/000110465923091407/0001104659-23-091407-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}